Tirzepatide is a man-made medicine that acts on two gut hormones at once — GIP and GLP-1 — to help control blood sugar and support weight loss. It belongs to a class of medicines called dual GIP/GLP-1 receptor agonists, used for type 2 diabetes and for chronic weight management. It is a prescription-only medicine.

• Therapeutic Class: Anti-diabetic and anti-obesity medicine.

• Pharmacological Class: Dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist.

• Drug Family: Incretin-based therapies.

• ATC Classification: A10BX16 (Tirzepatide).

Approved: Type 2 Diabetes (blood sugar control, brand Mounjaro), and chronic weight management in adults with obesity or who are overweight with a weight-related condition (brand Zepbound); also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Commonly used for: People with type 2 diabetes needing better blood sugar control, and people needing significant weight loss alongside diet and exercise.

Off-label use (only under medical guidance): Occasionally considered in other insulin-resistance-related conditions, though this is a doctor's decision, not routine use.

● Injection (pre-filled pen/vial): commonly available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths for once-weekly subcutaneous use.

Tirzepatide activates two natural gut hormone receptors, GIP and GLP-1, which together help the pancreas release insulin when needed, reduce appetite, and slow stomach emptying. This dual action produces steadier blood sugar control and more pronounced weight loss than single-hormone therapies.

• Standard starting dose: 2.5 mg once weekly for the first 4 weeks (for treatment initiation only, not for blood sugar or weight control).

• Condition-wise dose: Increased in 2.5 mg increments every 4 weeks as needed/tolerated, up to a maximum of 15 mg once weekly.

• Route: Subcutaneous injection (under the skin, in the abdomen/thigh/upper arm) once a week, on the same day each week.

• Missed dose: Can usually be taken within 4 days of the missed dose; if more than 4 days have passed, skip it and resume the regular schedule.

• Overdose: Can cause severe nausea, vomiting, and low blood sugar; needs urgent medical attention.

• Common: Nausea, diarrhoea, vomiting, constipation, reduced appetite, and injection-site reactions.

• Serious: Pancreatitis, gallbladder problems, kidney function changes, and severe allergic reactions; carries a boxed warning about thyroid C-cell tumours seen in rodent studies.

• Emergency symptoms: Severe stomach pain that doesn't go away, a lump or swelling in the neck, difficulty swallowing or breathing, or symptoms of very low blood sugar.

• Recovery advice: Nausea and stomach-related side effects are usually most noticeable during dose increases and often ease as the body adjusts; eating smaller, simpler meals can help.

• Pregnancy: Not recommended; should be stopped well before planning a pregnancy.

• Breastfeeding: Not recommended without medical advice.

• Liver disease: Used cautiously; monitored closely.

• Kidney disease: Used with caution, particularly during dose escalation, given the risk of dehydration from GI side effects.

• Elderly: Used with caution; more sensitive to effects than younger adults.

• Children: Approved for type 2 diabetes in children aged 10 and older; not established for weight management in children.

•  Insulin or sulfonylureas: increases the risk of low blood sugar; dose adjustment of these medicines may be needed.

• Oral contraceptive pills: tirzepatide slows stomach emptying, which may affect absorption of oral medicines.

• Cyclosporine and other narrow-therapeutic-index oral drugs: absorption may be affected due to delayed gastric emptying.

• Other GLP-1 or GIP receptor agonists: should not be combined with other tirzepatide-containing products or other GLP-1 agonists.

● Blood sugar levels (regular home/lab monitoring).

● HbA1c periodically.

● Kidney function tests.

● Weight and BMI tracking.

● Thyroid symptom check, especially with a personal/family history of thyroid issues.

Semaglutide, Liraglutide, Dulaglutide (GLP-1-only agonists, different mechanism/efficacy profile).

Often prescribed alongside metformin, basal insulin, or blood pressure/cholesterol medicines. Should never be combined with another GLP-1 or GIP receptor agonist.

● Type 2 Diabetes Medicines

● Weight Management Treatments

● GIP/GLP-1 Receptor Agonists

1. Weight Loss Super Drug Tirzepatide Available In India

2. Mounjaro Injection for Weight Loss

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806s031lbl.pdf

2. https://reference.medscape.com/drug/mounjaro-zepbound-tirzepatide-4000264

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.